$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.69% on an annualized basis producing an average annual return of 10.89%. Currently, Gilead Sciences has a market c
GeoVax Stock Rockets 50% on BARDA Award for COVID-19 Vaccine
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
As markets continue to reach new all-time highs, investors are constantly seeking opportunities that offer both stability and growth potential. With the S&P 500 and Nasdaq recently hitting new all-tim
Check Out What Whales Are Doing With AMGN
Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen.Looking at options history for Amgen (NASDAQ:AMGN) we detected 67 trades.If we consider the specifics of each trade,
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. (NASDAQ:INVA), citing the company's unique business model centered around royalties and healthcare assets.The company receives royalties from
Stifel Starts Celldex at Buy, Sees Lead Drug as Potential Blockbuster
Day One in Licensing Pact With MabCare for Cancer Therapy
Analyst Expectations For Incyte's Future
6 analysts have shared their evaluations of Incyte (NASDAQ:INCY) during the recent three months, expressing a mix of bullish and bearish perspectives.The table below provides a snapshot of their recen
Incyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 — Cantor Fitzgerald Reiterates → Neutral 05/23/2024 -12.27% Deutsche Bank → $55 Initiates Cove
FDA Approves Merck's Pneumococcal Vaccine As First Shot Designed For Adults
Monday, the FDA approved Merck & Co Inc's (NYSE: MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.It
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.
Pfizer Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/17/2024 67.1% Cantor Fitzgerald $45 → $45 Reiterates Overweight → Overweight 05/02/2024 7.69% Morgan St
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
BioNTech SE's (NASDAQ:BNTX) partner MediLink Therapeutics (Suzhou) Co., Ltd says the FDA has placed a partial clinical hold on the Phase 1 trial.The MediLink-sponsored trial evaluates the early-stage
Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
Magrolimab was the centerpiece of Gilead Sciences Inc's (NASDAQ:GILD) $4.9 billion buyout of Forty Seven Inc in March 2020.Magrolimab is a monoclonal antibody targeting CD47 for treating various types
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
Shares of cell therapy company Legend Biotech Corp (NASDAQ:LEGN) were trading lower on Monday, after being among the top pharma gainers in the first week of June.The company's Carvykti drug is likely
Market Analysis: Johnson & Johnson And Competitors In Pharmaceuticals Industry
In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive company evaluations. In this article, we will delve into an ext
In-Depth Examination Of 11 Analyst Recommendations For Johnson & Johnson
11 analysts have expressed a variety of opinions on Johnson & Johnson (NYSE:JNJ) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below provides a snapshot o
ITeos And GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug And Dostarlimab In Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer; Primary Endpoints Of The Trial Are Progression...
ITeos And GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug And Dostarlimab In Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Can
Johnson & Johnson Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/17/2024 20.35% RBC Capital $175 → $175 Reiterates Outperform → Outperform 06/04/2024 20.35% RBC Capital
U.S. Drug Shortages Worsen to Reach a Decade High: Report